| RELMADA THERAPEUT.DL-,001 |
| USA |
| Gesundheit |
| US75955J4022 / A2PSZF |
| 4E2 (Frankfurt) / RLMD (NASDAQ) |
| FRA:4E2, ETR:4E2, 4E2:GR, NASDAQ:RLMD |
| - |
| https://www.relmada.com/ |
|
Relmada Therapeutics Inc. is a clinical-stage biotechnology company dedicated to the development of treatments for neurological and psychiatric disorders. With a strong focus on addressing central ner..
>Volltext.. |
| 279.62 Mio. EUR |
| 267.79 Mio. EUR |
| - |
| -49.79 Mio. EUR |
| -48.35 Mio. EUR |
| -1.55 EUR |
| - |
| 1.19 Mio. EUR |
| -34.42 Mio. EUR |
| 2.68 |
| - |
| 38.37% |
| - |
| - |
| - |
| - |
| RELMADA |
| 09.03.26 |
|
||||
|